SEC 13F Intelligence

Managers / Q3 2023 · view latest →

Venrock Adviser, LLC

CIK 0001615982 · 7 BRYANT PARK, 23RD FLOOR, NEW YORK, NY, 10018 · 650-475-3734

Reported Value
$950M
Q3 2023
Positions
37
Filings on Record
28
2019–present window
Filed
Nov 14, 2023
original filing

Summary

Venrock Adviser, LLC reported $950M in U.S.-listed holdings across 37 positions for Q3 2023.

Its largest position, APGE, represents 19.0% of the portfolio.

Compared with Q2 2023, the fund opened 10 new positions and exited 3.

Portfolio Metrics

Turnover
+16.6%
vs prior filed quarter
Top-10 Concentration
+62.2%
share of reported value
Largest Position
+19.0%
Apogee Therapeutics
New / Exited
10 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’20: $369MQ1 ’20Q2 ’20: $418MQ3 ’20: $511MQ4 ’20: $680MQ1 ’21: $922MQ1 ’21Q2 ’21: $824MQ3 ’21: $779MQ4 ’21: $732MQ1 ’22: $617MQ1 ’22Q2 ’22: $554MQ3 ’22: $681MQ4 ’22: $623MQ1 ’23: $512MQ1 ’23Q2 ’23: $625MQ3 ’23: $950MQ4 ’23: $1.5BQ1 ’24: $2.1BQ1 ’24Q2 ’24: $1.6BQ3 ’24: $1.9BQ4 ’24: $1.5BQ1 ’25: $1.2BQ1 ’25Q2 ’25: $1.3BQ3 ’25: $1.8BQ4 ’25: $2.0BQ1 ’26: $2.7BQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 71.0%Other: 29.0%
  • Common Stock · 71.0% · $675M
  • Other · 29.0% · $275M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
APGEAPOGEE THERAPEUTICS INCNEW+8.49M8.49M+$181M$181M
RAYZEBIO INCNEW+4.02M4.02M+$89M$89M
TSHATAYSHA GENE THERAPIES INCNEW+14.44M14.44M+$46M$46M
HILLEVAX INCNEW+2.04M2.04M+$27M$27M
TVTXTRAVERE THERAPEUTICS INCNEW+2.62M2.62M+$23M$23M
MERSANA THERAPEUTICS INCNEW+11.33M11.33M+$14M$14M
DNTHDIANTHUS THERAPEUTICS INCNEW+927.7K927.7K+$13M$13M
ACELYRIN INCNEW+864.3K864.3K+$9M$9M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2023

37 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1APGEAPOGEE THERAPEUTICS INChistory →COM19.04%$181M8.49M
2RAYZEBIO INCCOM9.39%$89M4.02M
3VRDNVIRIDIAN THERAPEUTICS INChistory →COM4.98%$47M3.08M
4COGTCOGENT BIOSCIENCES INChistory →COM4.81%$46M4.68M
5TSHATAYSHA GENE THERAPIES INChistory →COM SHS4.80%$46M14.44M
6MERUS N VCOM4.28%$41M1.73M
7ELVNENLIVEN THERAPEUTICS INChistory →COM4.25%$40M2.95M
8FDMT4D MOLECULAR THERAPEUTICS INhistory →COM4.02%$38M3.00M
9PHARVARIS N VCOM3.43%$33M1.56M
10CABACABALETTA BIO INChistory →COM3.16%$30M1.97M
114XC1KALVISTA PHARMACEUTICALS INChistory →COM2.96%$28M2.92M
12GH RESEARCH PLCORDINARY SHARES2.90%$28M2.74M
13HILLEVAX INCCOM2.88%$27M2.04M
14YB4PSAVARA INChistory →COM2.86%$27M7.18M
15RYTMRHYTHM PHARMACEUTICALS INChistory →COM2.63%$25M1.09M
16AMBRX BIOPHARMA INCSPONSORED ADS2.51%$24M2.07M
17TVTXTRAVERE THERAPEUTICS INChistory →COM2.47%$23M2.62M
18DYNDYNE THERAPEUTICS INChistory →COM2.05%$19M2.17M
19CELCCELCUITY INChistory →COM2.03%$19M2.11M
20430TERNS PHARMACEUTICALS INChistory →COM1.64%$16M3.09M
21MERSANA THERAPEUTICS INCCOM1.51%$14M11.33M
22APLTAPPLIED THERAPEUTICS INChistory →COM1.48%$14M5.66M
23ORICORIC PHARMACEUTICALS INChistory →COM1.36%$13M2.14M
24DNTHDIANTHUS THERAPEUTICS INChistory →COM1.33%$13M927.7K
25ADVMCHFADVERUM BIOTECHNOLOGIES INChistory →COM1.04%$10M6.57M
26PRAXIS PRECISION MEDICINES ICOM0.95%$9M5.30M
27ACELYRIN INCCOM0.93%$9M864.3K
28TRVITREVI THERAPEUTICS INCCOM0.79%$7M3.42M
29ACRSACLARIS THERAPEUTICS INCCOM0.75%$7M1.04M
30MISTMILESTONE PHARMACEUTICALS INCOM0.72%$7M2.21M
31PLRXPLIANT THERAPEUTICS INCCOM0.53%$5M288.9K
32SGMTSAGIMET BIOSCIENCES INCCOM SER A0.48%$5M515.0K
33AGLEUSDAEGLEA BIOTHERAPEUTICS INCCOM0.38%$4M295.0K
34LYRA THERAPEUTICS INCCOM0.38%$4M924.2K
35OLMAOLEMA PHARMACEUTICALS INCCOM0.10%$951,46977.0K
36RALLYBIO CORPCOM0.10%$904,953268.5K
37AFFIMED N VCOM0.07%$682,7141.43M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$2.7B33May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$2.0B27Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.8B33Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$1.3B31Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$1.2B37May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$1.5B37Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$1.9B38Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.6B35Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.1B38May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$1.5B36Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$950M37Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$625M30Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$512M25May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$623M29Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$681M32Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$554M28Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$617M27May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$732M26Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$779M26Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$824M29Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$922M28May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$680M25Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$511M22Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$418M16Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$369M16May 15, 202013F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.